论文部分内容阅读
Objective:Baicalein had been proved to have anti-cancer activity in vitro and in vivo, including the inhibition of malignant proliferation, migration, adhesion and invasion of many kinds of cancer cel s. The special AT-rich sequence binding protein 1 (SATB1) is a tissue-specific expression of nuclear matrix-binding protein and is reported to be a breast cancer“gene group organizer”. Previous studies have shown that SATB1 is involved in the growth, metastasis and prognosis of breast cancer. The present study was aimed to investigate whether baicalein inhibits the proliferation and migration of MDA-MB-231 human breast cancer cel s through down-regulation of the SATB1 expression. Methods:MDA-MB-231 cel s were treated for 24 h, 48 h and 72 h with various concentrations of baicalein (0, 5, 10, 20, 40 and 80μM) respectively. Then, the proliferation and migration of MDA-MB-231 cel s fol owing treatment with baicalein were determined using colorimetric 3-(4, 5-dimethylthia-zol-2-yl) 2, 5-diphenyltetrazolium bromide (MTT) and wound healing assays. Thereafter, western blot analysis was performed to detect the changes of SATB1 protein expression in MDA-MB-231 cel s. Results:Along with the prolongation of time and increase of drug concentration, inhibitory ef ect of baicalein on proliferation and migration of MDA-MB-231 cel s gradual y in-creased, in a time-and dose-dependent manner (P